Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan + Furmonertinib in EGFR-mutant NSCLC
NCT07193160Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Nov 2025
- Primary completion
- Jul 2026
- Sponsor
- Fudan University
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC), sponsored by Fudan University. Primary endpoint: Objective Response Rate at 12 months. Planned start Nov 2025; status: not yet recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
sac-TMT + Furmonertinib
Sacituzumab Tirumotecan combined with Furmonertinib
03
Who it enrols
Adult patients with locally advanced or metastatic non-squamous EGFR-mutant NSCLC who have progressed on first-line third-generation EGFR-TKI therapy, with no active CNS metastasis.
04
Endpoints
Primary
Objective Response Rate
Secondary
Progression Free Survival
Duration of Response
Disease Control Rate
Overall Survival
Beyond the preview
Go deeper on NCT07193160.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07193160.